-
1
-
-
30044438368
-
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
-
Armstrong DK, Bundy B, Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354:34-43.
-
(2006)
N Engl J Med.
, vol.354
, pp. 34-43
-
-
Armstrong, D.K.1
Bundy, B.2
Wenzel, L.3
-
2
-
-
84882998935
-
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial
-
Katsumata N, Yasuda M, Isonishi S., et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013; 14:1020-1026.
-
(2013)
Lancet Oncol.
, vol.14
, pp. 1020-1026
-
-
Katsumata, N.1
Yasuda, M.2
Isonishi, S.3
-
3
-
-
84855425106
-
Incorporation of beva-cizumab in the primary treatment of ovarian cancer
-
Burger RA, Brady MF, Bookman M.A., et al. Incorporation of beva-cizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365:2473-2483.
-
(2011)
N Engl J Med.
, vol.365
, pp. 2473-2483
-
-
Burger, R.A.1
Brady, M.F.2
Bookman, M.A.3
-
4
-
-
84859523588
-
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
-
Ledermann J, Harter P, Gourley C., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012; 366:1382-1392.
-
(2012)
N Engl J Med.
, vol.366
, pp. 1382-1392
-
-
Ledermann, J.1
Harter, P.2
Gourley, C.3
-
5
-
-
57649115547
-
Cancer patient preferences for quality and length of life
-
Meropol NJ, Egleston BL, Buzaglo J.S., et al. Cancer patient preferences for quality and length of life. Cancer. 2008; 113:3459-3466.
-
(2008)
Cancer
, vol.113
, pp. 3459-3466
-
-
Meropol, N.J.1
Egleston, B.L.2
Buzaglo, J.S.3
-
6
-
-
58149092838
-
Decision making and quality of life in the treatment of cancer: A review
-
Zafar SY, Alexander SC, Weinfurt K.P., Schulman KA, Abernethy AP. Decision making and quality of life in the treatment of cancer: a review. Support Care Cancer. 2009; 17:117-127.
-
(2009)
Support Care Cancer
, vol.17
, pp. 117-127
-
-
Zafar, S.Y.1
Alexander, S.C.2
Weinfurt, K.P.3
Schulman, K.A.4
Abernethy, A.P.5
-
7
-
-
0030248005
-
Patients' preferences for therapy in advanced epithelial ovarian cancer: Development, testing, and application of a bedside decision instrument
-
Elit LM, Levine MN, Gafni A, et al. Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument. Gynecol Oncol. 1996; 62:329-335.
-
(1996)
Gynecol Oncol.
, vol.62
, pp. 329-335
-
-
Elit, L.M.1
Levine, M.N.2
Gafni, A.3
-
8
-
-
84892795291
-
Ovarian cancer clinical trial endpoints: Society of gynecologic oncology white paper
-
Herzog TJ, Armstrong DK, Brady M.F., et al. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol. 2014; 132:8-17.
-
(2014)
Gynecol Oncol.
, vol.132
, pp. 8-17
-
-
Herzog, T.J.1
Armstrong, D.K.2
Brady, M.F.3
-
9
-
-
79959944619
-
Conjoint analysis applications in health - A checklist: A report of the ISPOR good research practices for conjoint analysis task force
-
Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health-a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011; 14: 403-413.
-
(2011)
Value Health
, vol.14
, pp. 403-413
-
-
Bridges, J.F.1
Hauber, A.B.2
Marshall, D.3
-
10
-
-
0035868845
-
Reliability and validity of the functional assessment of cancer therapy-ovarian
-
Basen-Engquist K, Bodurka-Bevers D, Fitzgerald M.A., et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Ovarian. J Clin Oncol. 2001; 19:1809-1817.
-
(2001)
J Clin Oncol.
, vol.19
, pp. 1809-1817
-
-
Basen-Engquist, K.1
Bodurka-Bevers, D.2
Fitzgerald, M.A.3
-
11
-
-
0034306866
-
Assessing symptom distress in cancer patients: The MD anderson symptom inventory
-
Cleeland CS, Mendoza TR, Wang X.S., et al. Assessing symptom distress in cancer patients: the MD Anderson Symptom Inventory. Cancer. 2000; 89:1634-1646.
-
(2000)
Cancer
, vol.89
, pp. 1634-1646
-
-
Cleeland, C.S.1
Mendoza, T.R.2
Wang, X.S.3
-
12
-
-
0034600459
-
Using conjoint analysis to elicit preferences for health care
-
Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ. 2000; 320:1530-1533.
-
(2000)
BMJ
, vol.320
, pp. 1530-1533
-
-
Ryan, M.1
Farrar, S.2
-
13
-
-
84861719741
-
Patients' preferences for treatment outcomes for advanced nonsmall cell lung cancer: A conjoint analysis
-
Bridges JF, Mohamed AF, Finnern H.W., Woehl A., Hauber AB. Patients' preferences for treatment outcomes for advanced nonsmall cell lung cancer: a conjoint analysis. Lung Cancer. 2012; 77:224-231.
-
(2012)
Lung Cancer
, vol.77
, pp. 224-231
-
-
Bridges, J.F.1
Mohamed, A.F.2
Finnern, H.W.3
Woehl, A.4
Hauber, A.B.5
-
14
-
-
84855545457
-
Discrete choice experiments in health economics: A review of the literature
-
de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012; 21:145-172.
-
(2012)
Health Econ.
, vol.21
, pp. 145-172
-
-
De Bekker-Grob, E.W.1
Ryan, M.2
Gerard, K.3
-
15
-
-
84872731697
-
Constructing experimental designs for discrete-choice experiments: Report of the ISPOR conjoint analysis experimental design good research practices task force
-
Reed Johnson F, Lancsar E, Marshall D., et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013; 16:3-13.
-
(2013)
Value Health
, vol.16
, pp. 3-13
-
-
Reed Johnson, F.1
Lancsar, E.2
Marshall, D.3
-
16
-
-
80051913984
-
2010 gynecologic cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: Report from the fourth ovarian cancer consensus conference
-
Stuart GC, Kitchener H, Bacon M., et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011; 21:750-755.
-
(2011)
Int J Gynecol Cancer
, vol.21
, pp. 750-755
-
-
Stuart, G.C.1
Kitchener, H.2
Bacon, M.3
-
17
-
-
0141688377
-
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A gynecologic oncology group study
-
Ozols RF, Bundy BN, Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21:3194-3200.
-
(2003)
J Clin Oncol.
, vol.21
, pp. 3194-3200
-
-
Ozols, R.F.1
Bundy, B.N.2
Greer, B.E.3
-
18
-
-
58849091878
-
Using conjoint analysis to estimate healthy-year equivalents for acute conditions: An application to vasomotor symptoms
-
Johnson FR, Hauber AB, Ozdemir S. Using conjoint analysis to estimate healthy-year equivalents for acute conditions: an application to vasomotor symptoms. Value Health. 2009; 12:146-152.
-
(2009)
Value Health
, vol.12
, pp. 146-152
-
-
Johnson, F.R.1
Hauber, A.B.2
Ozdemir, S.3
-
19
-
-
84873744492
-
Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A gynecologic oncology group study
-
Monk BJ, Huang HQ, Burger R.A., et al. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013; 128:573-578.
-
(2013)
Gynecol Oncol.
, vol.128
, pp. 573-578
-
-
Monk, B.J.1
Huang, H.Q.2
Burger, R.A.3
-
20
-
-
84893639983
-
Patient preferences for surgical versus medical therapy for ulcerative colitis
-
Bewtra M, Kilambi V, Fairchild A.O., Siegel CA, Lewis JD, Johnson FR. Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis. 2014; 20:103-114.
-
(2014)
Inflamm Bowel Dis.
, vol.20
, pp. 103-114
-
-
Bewtra, M.1
Kilambi, V.2
Fairchild, A.O.3
Siegel, C.A.4
Lewis, J.D.5
Johnson, F.R.6
-
21
-
-
1542289007
-
A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer
-
Cole BF, Gelber RD, Gelber S, Mukhopadhyay P. A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer. J Biopharm Stat. 2004; 14:111-124.
-
(2004)
J Biopharm Stat.
, vol.14
, pp. 111-124
-
-
Cole, B.F.1
Gelber, R.D.2
Gelber, S.3
Mukhopadhyay, P.4
-
22
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
-
Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15:2403-2413.
-
(1997)
J Clin Oncol.
, vol.15
, pp. 2403-2413
-
-
Burris, H.A.1
Moore, M.J.2
Andersen, J.3
-
23
-
-
68749107026
-
Clinical benefit in oncology trials: Is this a patient-centred or tumour-centred end-point?
-
Ohorodnyk P, Eisenhauer EA, Booth CM. Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point? Eur J Cancer. 2009; 45:2249-2252.
-
(2009)
Eur J Cancer
, vol.45
, pp. 2249-2252
-
-
Ohorodnyk, P.1
Eisenhauer, E.A.2
Booth, C.M.3
|